Stay updated on Daratumumab for AML/High-Risk MDS Clinical Trial

Sign up to get notified when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab for AML/High-Risk MDS Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The record describes a phase 2 study of daratumumab for relapsed or refractory blood cancers, including its eligibility criteria, treatment plan, outcomes, and study results. It also shows that the study was terminated early for lack of efficacy and is no longer recruiting.
    Difference
    45%
    Check dated 2026-11-08T02:26:44.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T22:26:33.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A notice was added announcing NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T22:28:26.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision indicator changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T22:28:01.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.0 to v3.7.1; the page still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T22:21:13.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    The study record page displays a 403 Forbidden message and a Home link in its main content area.
    Difference
    0.5%
    Check dated 2026-10-03T22:09:06.000Z thumbnail image

Stay in the know with updates to Daratumumab for AML/High-Risk MDS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.